Literature DB >> 18387790

Combining fulvestrant (Faslodex) with continued oestrogen suppression in endocrine-sensitive advanced breast cancer: the SoFEA trial.

D Dodwell, G Coombes, J M Bliss, L S Kilburn, S Johnston.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2008        PMID： 18387790     DOI： 10.1016/j.clon.2008.02.010

Source DB:  PubMed          Journal:  Clin Oncol (R Coll Radiol)        ISSN： 0936-6555            Impact factor:   4.126


× No keyword cloud information.
  4 in total

Review 1.  Fulvestrant: a review of its use in the management of hormone receptor-positive metastatic breast cancer in postmenopausal women.

Authors:  Jamie D Croxtall; Kate McKeage
Journal:  Drugs       Date:  2011-02-12       Impact factor: 9.546

2.  Models and Mechanisms of Acquired Antihormone Resistance in Breast Cancer: Significant Clinical Progress Despite Limitations.

Authors:  Elizabeth E Sweeney; Russell E McDaniel; Philipp Y Maximov; Ping Fan; V Craig Jordan
Journal:  Horm Mol Biol Clin Investig       Date:  2012-02

3.  ERα-dependent E2F transcription can mediate resistance to estrogen deprivation in human breast cancer.

Authors:  Todd W Miller; Justin M Balko; Emily M Fox; Zara Ghazoui; Anita Dunbier; Helen Anderson; Mitch Dowsett; Aixiang Jiang; R Adam Smith; Sauveur-Michel Maira; H Charles Manning; Ana M González-Angulo; Gordon B Mills; Catherine Higham; Siprachanh Chanthaphaychith; Maria G Kuba; William R Miller; Yu Shyr; Carlos L Arteaga
Journal:  Cancer Discov       Date:  2011-07-20       Impact factor: 39.397

4.  Stability Indicating HPLC Method for the Determination of Fulvestrant in Pharmaceutical Formulation in Comparison with Linear Sweep Voltammetric Method.

Authors:  Alptug Atila; Bilal Yilmaz; Yucel Kadioglu
Journal:  Iran J Pharm Res       Date:  2016       Impact factor: 1.696
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.